Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verastem, Inc.VSTM · Entity 5242 | Director · President and CEO | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verastem, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 652,712 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Grant · Disposed 106,893 · Balance 696,833 F1: The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved. Row 2 · 2026-10-01 · Sale · Disposed 44,121 · Balance 652,712 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2018 Filed Jan 9, 2018 22:51 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-18-001514 · a4.xml · derivative · entry 1 Paterson Dan · CIK 0001563202 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-05 F1 · derivative.exercise_date: 25% of this option will vest on January 1, 2019 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 1, 2022. Read SEC document |
| September 19, 2017 Filed Sep 21, 2017 20:02 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001104659-17-058284 · a4.xml · derivative · entry 1 Paterson Dan · CIK 0001563202 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2026-06-14 F1 · balance_after: On June 14, 2016, the Reporting Person was granted an option to purchase 100,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by the end of June, 2017 and the end of June, 2018. 50% of the performance criteria was met on September 19, 2017, resulting in vesting of the option as to 50,000 shares. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 22:01 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001104659-17-001977 · a4.xml · derivative · entry 1 Paterson Dan · CIK 0001563202 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-09 F1 · derivative.exercise_date: 25% of this option will vest on January 9, 2018 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 9, 2021. Read SEC document |
| October 29, 2016 Filed Nov 2, 2016 00:13 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001104659-16-153854 · a4.xml · derivative · entry 1 Paterson Dan · CIK 0001563202 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-06-14 F1 · balance_after: On June 14, 2016, the Reporting Person was granted an option to purchase 100,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by the end of June, 2017 and the end of June, 2018. 50% of the performance criteria was met on October 29, 2016, resulting in vesting of the option as to 50,000 shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.